Dermapharm Holding SE - M&A Activity 2019

News Details

Ad-hoc | 6 June 2019 17:45

Dermapharm Holding SE:

Dermapharm Holding SE / Key word(s): Investment

Dermapharm Holding SE:

06-Jun-2019 / 17:45 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

**Disclosure of insider information pursuant to Section17 (1) 1 of the EU Regulation

no. 596/2014 on market abuse as amended (Market Abuse Regulation -MAR)**

Dermapharm Holding SE acquires a stake in fitvia

Grünwald, June 06, 2019 – Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) via Dermapharm AG concluded an agreement today to acquire a majority stake in fitvia GmbH, a company headquartered in Wiesbaden, Germany. With closing of the transaction, Dermapharm AG is acquiring 70.00 percent of the shares in the company specialized in healthy nutrition. The parties have agreed not to disclose the purchase price.

The purchase agreement is still subject to the approval of the antitrust authority. The Management Board expects the transaction to be completed in the third quarter of 2019.

>End of ad hoc announcement<

Contacts


Investor Relations Britta Hamberger Tel.: +49 (0)89 – 64186-233 Fax: +49 (0)89 – 64186-165 e-mail: [email protected]	cometis AG Claudius Krause Tel.: +49 (0)611 – 205855-28 Fax: +49 (0)611 – 205855-66 e-mail: [email protected]

06-Jun-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.dgap.de


Language:	English
Company:	Dermapharm Holding SE
	Lil-Dagover-Ring 7
	82031 Grünwald
	Germany
Phone:	+49 (0)89 64 86-0
E-mail:	[email protected]
Internet:	ir.dermapharm.de
ISIN:	DE000A2GS5D8
WKN:	A2GS5D
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange
EQS News ID:	820967